CHEMICAL RESEARCH IN THE DEVELOPMENT OF NEW ANTICANCER DRUGS

阿糖胞苷，一种在这个实验室合成的药物，即将开始 在三家机构进行I期临床试验。 一项专利申请描述了4- 去氨基胞苷（zebularine）。 一种双苯海因，比 在HL-60细胞的分化中，HMBA的作用比HMBA强， 专利申请 环戊烯基胞嘧啶（CPE-C）具有良好的临床前 抗肿瘤活性以及对两种DNA的有效活性 RNA病毒。 一项关于这种潜力的专利申请被提交 临床抗肿瘤候选者。

Ara-AC, a drug synthesized in this laboratory, is about to begin Phase I clinical trials in three institutions. A patent application describing the antiviral activity of 4- deaminocytidine (zebularine) was filed. A hexamethylene bis-hydantion, which was 10 times more potent than HMBA in differentiating HL-60 cells, was the subject of a patent application. Cyclopentenyl cytosine (CPE-C) has excellent preclinical antitumor activity as well as potent activity against both DNA and RNA viruses. A patent application was filed on this potential clinical antitumor candidate.